THE EFFICACY OF PREPROCEDURAL ORAL RINSE ON SARS-COV-2 VIRAL LOAD

Nicy Annie Varghese, BDS

Department of Otolaryngology-Head and Neck Surgery
McGill University, Montreal

August 2021

A thesis submitted to McGill University in partial fulfillment of the requirements of the degree of Master of Science

TABLE OF CONTENTS

ACKNOWLEDGEMENTS

I am taking this opportunity to glorify my Heavenly Father for all the blessings He has showered on me. I am grateful and thankful for directing my paths and guiding me through every step of my life. I pray that in all I do I would be able to testify You my Lord God Almighty. I thank You for bringing me this far and I trust in Your ways for my future.

I would like to extend my gratitude to my supervisor, Dr. Sam J Daniel for guiding me through these entire studies. Without his encouragement and enormous support, this thesis work could not have been completed. I express my sincere gratitude to my mentor and thesis committee member Dr. Sabrina Wurzba for the countless hours she has dedicated for the work without which this would not have been fruitful. I am grateful to Dr. Bernard Segal, for his generous guidance and mentorship through developing the thesis. I would like to thank my co- supervisor, Dr. Beatriz Ferraz dos Santos and Dr Yolène Lacroix, my thesis committee member for their insightful comments.

I am thankful to the Department of Otolaryngology for giving me this opportunity and a special thanks to the MAB-Mackay rehabilitation centre, and the saliva management clinic for the assistance they provided during this study. I am also thankful to the Montreal Children's Hospital library staff especially Taline Ekmekjian who helped me through the literature search. I take this opportunity to thank my supportive friends and colleagues in the McGill Otolaryngology Sciences laboratory.

I would like to extend my deepest gratitude to my papa Mr. M K Varghese and my mama Mrs. Annamma Koshy for believing me and for their love, care, support, and prayers for me. My husband Mr. Siju Philip, thank you so much for trusting in me and my capabilities and encouraging me to achieve more. Jayden and Jade our little love, are our source of joy. Thank you for understanding me and being with me through this stage of my life. I once again take this opportunity to thank each and every one of you who have played an important part for this thesis work.

ABSTRACT

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing COVID-19, has affected high exposure healthcare professionals leading in certain cases to severe respiratory infection, sepsis, and even death. The high viral load in secretions and droplet splatter from infected persons can increase the risk of direct transmission of SARS-CoV-2 especially to the healthcare professionals in close contact with patients. Additionally, aerosol generating medical procedures (AGMP) increase the transmission through contaminated surfaces.

Objective: Considering the contemporary pandemic crisis, this thesis aimed to do a systematic literature search to evaluate if using a preoperative antiseptic oral rinse in infected patients minimizes the risk of COVID-19 transmission to healthcare professionals.

Method: A systematic literature search was performed to evaluate antiseptic oral rinse efficacy in minimizing the transmission of SARS-CoV-2 viral load from patients to healthcare workers while performing AGMP.

Results: Fifty-five articles were reviewed, and 24 articles met the inclusion criteria. Products tested that showed wide-ranging efficacy against SARS-CoV-2 included povidone-iodine (PVP-I), chlorhexidine (CHX), hydrogen peroxide (H_2O_2), essential oils, and quaternary ammonium compounds (CPC). The majority of the publications were *in vitro* studies using different types and concentrations of products, different time of exposition and different strains of the family *Coronaviridae*. Seven studies consistently concluded that PVP-I was the most effective preprocedural mouth rinse to reduce the viral load in saliva.

Conclusion: Oral rinses can reduce COVID-19 transmission; however, their effectiveness in *in vivo* conditions is unknown. Due to the substantial heterogeneity reporting anti–SARS-CoV-2 efficacy of oral rinses, this systematic review highlights the need to conduct further clinical trials and basic research with robust and standardized methodologies to confirm effectiveness of oral rinses.

Keywords: Coronavirus, COVID-19, SARS-CoV-2, mouthwash, oral rinse, prevention

RÉSUMÉ

Introduction : Le SRAS-CoV-2, virus à l'origine de la COVID-19, a notamment touché les professionnels de santé hautement exposés, entraînant parmi eux des infections respiratoires sévères, des septicémies et même des décès. Une charge virale élevée dans les sécrétions rhinopharyngées, salivaires ou dans les gouttelettes respiratoires des patients infectés peut augmenter le risque de transmission directe du SRAS-CoV-2, particulièrement chez les professionnels de santé qui ont un contact étroit avec les patients. De plus, les procédures médicales générant des aérosols (AGMP) sont associées à un risque accru de transmission du virus par voie directe ou par l'intermédiaire de surfaces contaminées.

Objectif : Compte tenu de la crise pandémique contemporaine, cette thèse visait à effectuer une recherche documentaire systématique pour évaluer si l'utilisation d'un rince-bouche antiseptique préopératoire chez les patients infectés minimise le risque de transmission du COVID-19 aux professionnels de santé.

Méthode : Une recherche documentaire systématique a été effectuée pour évaluer l'efficacité du rince-bouche antiseptique pour minimiser la transmission de la charge virale du SRAS-CoV-2 des patients aux travailleurs de la santé lors de l'exécution de l'AGMP.

Résultats : Parmi les cinquante-cinq articles identifiés, 24 ont été inclus dans l'étude. Les 31 restants ne correspondaient pas à nos critères d'inclusion. Les produits testés comprenaient de la povidone-iode (PVP-I), de la chlorhexidine (CHX), du peroxyde d'hydrogène (H_2O_2), des huiles essentielles et des composés d'ammonium quaternaire (CPC). Tous se sont avérés très efficaces contre le SRAS-CoV-2. La majorité des publications étaient des études in vitro impliquant différentes concentrations de produits, un temps d'exposition variable et différents variant de la famille des Coronaviridae. Sept études ont conclu que la PVP-I était le rince bouche préopératoire le plus efficace pour réduire la charge virale dans la salive.

Conclusion : Les rince bouche semblent réduire la transmission de la COVID-19 ; cependant, l'efficacité in vivo reste à ce jour inconnue. En raison de l'hétérogénéité considérable des études portant sur l'efficacité des rince bouche pour réduire la transmission de SRAS-CoV-2, cette revue

souligne la nécessité de poursuivre la recherche fondamentale et de réaliser des essais cliniques avec méthodologie robuste et standardisée pour confirmer l'efficacité des rince bouche sur la diminution de la transmission du SRAS-CoV-2.

Mots clés : Coronavirus, COVID-19, SARS-CoV-2, rince bouche, povidone-iode, prévention.

LIST OF FIGURES AND TABLES

.

LIST OF ABBREVIATIONS

ADA- American Dental Association

AGMP- Aerosol Generating Medical Procedures

BZK- Benzalkonium Chloride

CDC- Centers For Disease Control And Prevention)

CHX- Chlorhexidine

COVID-19- Coronavirus Disease

CPC- Cetylpyridinium Chloride

DQ- Dequalinium Chloride

ELISA- Enzyme-Linked Immunosorbent Assay

H2O2- Hydrogen Peroxide

ICTV - International Committee On Taxonomy Of Viruses

LF- Lactoferrin

OCT- Octenident

OSCN- Hypothiocyanite

PAPB- Polyaminopropyl Biguanide

PPE- Personal Protective Equipment

PVP-I -Povidone Iodine

RT-PCR- Reverse Transcription Polymerase Chain Reaction

SARS-Cov-2- Severe Acute Respiratory Syndrome Coronavirus 2

WHO – World Health Organization

CHAPTER 1

INTRODUCTION

1.1 Background and Thesis Rationale

In early December 2019, patients started to present with severe acute pneumonia leading to fast sepsis death due to a new virus identified in Wuhan, China (Azzi *et al*, 2020)]. The International Committee on Taxonomy of Viruses documented it as a variant of SARS-CoV, hence named it SARS-CoV-2(Peiris 2021). The World Health Organization (WHO) called the infectious disease caused by the newly discovered coronavirus "COVID-19", or coronavirus disease 2019 (Harapan *et al*, 2020). SARS-CoV-2 became the seventh coronavirus that infects humans, especially vulnerable individuals with comorbidities and high-risk exposure healthcare professionals (Harapan *et al*, 2020). In 2021, it is a contagious viral infection that is continuing to spread around the world, with thus far more than 167 million confirmed cases and three million deaths (https://www.who.int/health-topics/coronavirus).

The mode of transmission is through the respiratory tract, mainly through human-to-human airborne transmission while coughing, sneezing, conversing close by, and even breathing near to each other (1-3 meters) ((Peiris 2021). The incubation period is typically 1-14 days. The virus has been isolated from different secretions, such as saliva (Azzi *et al* 2020, To *et al* 2020), blood (Young *et al*, 2020), stool (Holshue *et al,* 2020), and tears (Xiao *et al*,2020). Laboratory tests to detect SARS-CoV-2 are genome sequencing, reverse-transcription polymerase chain reaction (RT-PCR), and enzyme-linked immunoassay (ELISA). Due to cost and practicality, the RT-PCR is the most used method worldwide to detect spike proteins and the N gene of this virus (Young *et al*, 2020). The salivary aerosols pose a threat to healthcare providers who operate close to face and oral cavities. High-risk healthcare professionals include dental practitioners, oral-maxillofacial surgeons, otolaryngologists, and ophthalmologists (Bescos *et al,* 2020) [10]. Personal protection equipment (PPE), personal hygiene, infection control in the environment, and physical distancing are crucial in mitigating infection transmission (Harapan *et al*, 2020). Recently, the US Centers for Disease Control (CDC) and the American Dental Association (ADA) have recommended preprocedural prophylactic rinses to potentially reduce the SARS-CoV-2 viral load (To *et al* 2020).

However, the relative effectiveness of such rinses is currently uncertain. This uncertainty was the **rationale** of this thesis and led to the thesis objective stated in the following section.

1.2 Objective of this Thesis

Due to the above issues, and considering the current pandemic crisis, the objective of this thesis is to do a systematic literature search to evaluate if using preoperative antiseptic oral rinse in infected patients minimizes the risk of COVID-19 transmission to healthcare professionals.

CHAPTER 2

LITERATURE REVIEW

2.1 Coronavirus

Coronaviruses are a large group of viruses commonly found among many animals, including humans. They can cause respiratory illnesses in humans and gastrointestinal illnesses in animals. Coronavirus was first discovered in domesticated chickens with an acute respiratory infection caused by infectious bronchitis virus (IBV) in early 1930s (Peiris, 2012). In 1965, Tyrrell and Bynoe were able to cultivate the human coronavirus virus from nasal washings of patients with the common cold by inoculating them into organ cultures of human foetal tracheal or nasal epithelium (Tyrrell & Bynoe, 1966). Further studies with animal viruses (e.g. mouse hepatitis virus, transmissible gastroenteritis swine virus) and human viruses (e.g. bronchitis virus) showed that all of them exhibited similar morphology under electron microscopy after negative staining. They have large peplomers that make a crown-like appearance on the surface, hence the name corona, meaning "crown" or "halo". This gave the new group of virus the name coronavirus (Latin- Crown) which was later accepted as a new genus (Lefkowitz *et al.*, 2018) (**Figure 1**).



Figure 1: Coronavirus structure (Created with BioRender)

Before 2003, human coronavirus were not considered a deadly virus. The circulating strains were causing mild symptoms in people who were immunocompromised, such as common cold or mild respiratory illness (Ison & Lee, 2017). Typically, coronavirus symptoms include runny nose, cough, sore throat, headache, and fever that can last for several days. However, in immunocompromised patients, there is a chance that the virus can cause a lower respiratory illness, like pneumonia and bronchitis (Wang *et al*,2006). However, in 2003, the world was shocked by the first pandemic of the 21st century; with the spread of the then new infection Severe Acute Respiratory Syndrome (SARS-CoV), emerged in Guangdong, China, resulting in 774 deaths and more than 8000 people infected (Cui *et al* , 2018). Studies showed that SARS-CoV has a potential and tendency to cross species barriers, and to undergo zoonotic transformation to infect new animal species, or humans, with serious outbreaks of respiratory diseases and high virulence (MacKenzie & Smith, 2020). Coronavirus typically presents as a self-limiting respiratory, gastrointestinal, neurological, or other systemic diseases in the infected host. Human coronaviruses identified after SARS- CoV in 2003 are: HCoV NL63 in 2004, HCoV HKU1 in 2005, MERS-CoV in 2012, and SARS-CoV-2 in 2019 (Lefkowitz *et al.*, 2018) (**Figure 2**).



Figure 2: The timeline of the emerging coronavirus. The origin of the history of coronaviruses is pinpointed in the 1930s, when the avian infectious bronchitis (IBV) was first detected in humans. The progression and development of coronaviruses continued to the 1940s (detection of murine hepatitis virus and transmissible gastroenteritis virus), the 1960s (detection of HCoV-B814, HCoV-229E, and HCoV-OC43), 2003(detection of SARS-CoV or SARS-CoV-1), 2004 (detection of HCoV-NL63), 2005 (detection of HCoV-HKU1), 2012 (detection of MERS), and 2019 (detection of SARS-CoV-2)(Kooshkaki et al. 2020).

2.2 Property of coronavirus

The transmission of coronavirus happens when virus carriers shed the virus into the environment through an aerosol, fomite, or fecal-oral route (Gralinski & Baric, 2015). The virus spreads by human-to-human transmission through droplet, or direct contact, but a plausible interspecies transmission mechanism of the virus is not yet fully understood (Pascarella *et al*,2020). When exposed, a mean incubation period of 6.4 days until clinical signs appear is confirmed. In models of the transmission process of SARS-CoV-2, the reproduction number (R_0, the number of new infections estimated to stem from a single case) was predicted to be in the range of 2.24 and 3.58, depending on the exponential growth from the starting date (Zhuang *et al* ,2020). Epithelial cells are the usual target of a coronavirus - respiratory epithelial cells in case of humans, and digestive tract epithelial cells of animals (Weiss & Leibowitz, 2011) (**Figure 3**).

Coronaviruses are able to undergo genetic recombination when a minimum of two viral genomes are present in the same infected cell (Tortorici & Veesler, 2019). The genome of the virus undergoes the process known as RNA recombination which combines with the genome of the two types of pathogenic virus having the properties of both (Burrell *et al.*, 2017). This recombinant virus then jumps from one host to another causing the formation of new or novel coronavirus species (MacKenzie & Smith, 2020).



Figure 3: Mode of transmission of SARS-CoV-2 virus (Reprinted with permission Source: https://world-heart-federation.org/resource/covid-19-transmission/)

2.3 Structure of coronavirus

The shape of coronavirus is spherical, enclosing a single-stranded positive-sense RNA (+ssRNA) molecule (**Figure 4**). Genome sizes range between 27–32 kbp, one of the largest known RNA viruses (de Groot *et al.*, 2012). The genomic structure of coronaviruses contains at least six open reading frames (ORFs). The first ORFs (ORF1a/b), located at the 5′ end, about two-thirds of the whole genome length, and encodes a polyprotein 1a,b (pp1a, pp1b) (Masters *et al,* 2006). Other ORFs are located on 3′ end encodes at least four major structural proteins: spike (S), membrane (M), envelope (E) and the nucleocapsid (N) protein, all of which are encoded within the 3' end of the genome (**Figure 4**). The S protein mediates attachment of the virus to the host cell surface receptors resulting in fusion and subsequent viral entry. The M protein is the most abundant protein and defines the shape of the viral envelope. The E protein is the smallest of the major structural proteins and participates in viral assembly and budding. The N protein is the only one that binds to the RNA genome and is also involved in viral assembly and budding. In addition to the four main structural proteins, there are structural and accessory proteins that are species-specific, such as HE protein, 3a/b protein, and 4a/b protein (Chen *et al,* 2020). Once the viral genome enters the cytoplasm of the target cell, and given it is a positive-sense RNA genome, it translates into two polyproteins 1a, b (pp1a, pp1b). These polyproteins are processed into 16 non-structural proteins (NSPs) to form a replication-transcription complex (RTC) that is involved in genome transcription and replication. Consequently, a nested set of subgenomic RNAs (sgRNAs) is synthesized by RTC in the form of discontinuous transcription (Chen *et al,* 2020).



Figure 4. The genomic organization of SARS-CoV-2. (Created with BioRender).

The genome encodes two large genes ORF1a (yellow), ORF1b (blue), which encode 16 non-structural proteins (NSP1– NSP16). These NSPs are processed to form a replication–transcription complex (RTC) that is involved in genome transcription and replication. For example, NSP3 and NSP5 encode for Papain-like protease (PLP) and 3CL-protease, respectively. Both proteins function in polypeptides cleaving and block the host innate immune response. NSP12 encodes for RNA-dependent RNA polymerase (RdRp). NSP15 encodes for RNA helicase. The structural genes encode the structural proteins, spike (S), envelope (E), membrane (M), and nucleocapsid (N), highlighted in green. The accessory proteins (shades of grey) are unique to SARS-CoV-2 in terms of number, genomic organization, sequence, and function (Alanagreh et al. 2020).

2.4 Replication cycle of the coronavirus

Replication of coronaviruses begin with the attachment of the virus to the host cell and entry (**Figure 5**). SARS-CoV-2 primarily infects ciliated bronchial epithelial cells and type II pneumocytes, where it binds to the specific surface receptor, angiotensin-converting enzyme 2 (ACE2), through S glycoprotein found on its surface (Hoffmann *et al,* 2020) (Li *et al* ,2003) (Qian *et al* ,2013) (Letko *et al,* 2020). When S glycoprotein binds to the ACE2, the cleavage of trimer S protein is triggered by the cell surface-associated transmembrane protease serine 2 (TMPRSS2)

and cathepsin. S glycoprotein includes two subunits, S1 and S2. S1 determines the host range and cellular tropism and facilitates viral attachment to the target cells. S2 is a unit that mediates the fusion of viral and cellular membranes, ensuring viral entry through endocytosis (Hoffmann *et al,* 2020). The affinity between the virus' surface proteins and its receptors is a critical step for viral entry. A recent study showed that the affinity between S glycoprotein of SARS-CoV-2 and ACE2 binding efficiency is 10–20 fold higher than that of SARS-CoV, which could explain the highly infectious ability of SARS-CoV-2 (Letko *et al,* 2020). The next step is the translation of the replicase gene from the virion genomic RNA. Once the cleavage of the virus is done by the host cells, the genome in the virus enters the cytoplasm of the cell. The 5'mehtylated cap and 3' polyadenylated tail of the RNA genome allows the attachment of the RNA into the ribosome of the host cell for translation (Tortorici & Veesler, 2019). It translates the overlapping of the virus genome and creates a long polyprotein. This further cleaves into numerous non-structural proteins and assembly of the viral replicase complexes (RTC) (Snijder *et al.*, 2016). The exoribonuclease non-structural protein assists by providing extra fidelity to the replication process (Benjamin W. Neuman *et al.*, 2014). The replication of these positive single-stranded RNA to negative sense RNA genome happens with the help of *RNA dependent RNA polymerase* (RdRp) (Benjamin W. Neuman *et al.*, 2014) (Snijder *et al.*, 2016). Following replication and subgenomic RNA synthesis, the encapsulation occurs resulting in the formation of the mature virus. The S, E and M proteins them moves into the Golgi apparatus of the host cell. Here the M protein assembles the virus, and the pathogenic virus is released by the host cell by the secretory vesicles through exocytosis (Masters, 2006). This process allows more virus to enter the host cell (Tortorici & Veesler, 2019).



Figure 5. The life cycle of SARS-CoV-2 in the host cells. (Created with BioRender)

The S glycoproteins of the virion bind to the cellular receptor angiotensin-converting enzyme 2 (ACE2) and enters target cells through an endosomal pathway. Following the entry of the virus into the host cell, the viral RNA is unveiled in the cytoplasm. ORF1a and ORF1ab are translated to produce pp1a and pp1ab polyproteins, which are cleaved by the proteases of the RTC. During replication, RTC drives the production full length (−) RNA copies of the genome and used as templates for full-length (+) RNA genomes. During transcription, a nested set of sub-genomic RNAs (sgRNAs), is produced in a manner of discontinuous transcription (fragmented transcription). Even though these sgRNAs may have several open reading frames (ORFs), only the closest ORF (to the 5′ end) will be translated. Following the production of SARS-CoV-2 structural proteins, nucleocapsids are assembled in the cytoplasm and followed by budding into the lumen of the endoplasmic reticulum (ER)–Golgi intermediate compartment. Virions are then released from the infected cell through exocytosis (Alanagreh et al. 2020).

2.5 Classification of Coronavirus

The International Committee on Taxonomy of Viruses (ICTV) has now classified and approved over 6590 species of viruses (Lefkowitz *et al.*, 2018). All the viruses are further divided into realms, kingdoms, phyla, subphyla, classes, orders, suborders, and families. Order nidovirales consist of the family coronaviridae with two subfamilies, coronavirinae and torovirinae depending on its shape. The spherical ones are coronavirus and the disc, kidney or rod-shaped ones are toroviruses. The subfamily coronavirinae is subdivided into four genera. The genus Alpha coronavirus has the human coronavirus (HCoV)-229E and HCoV-NL63 , Beta coronavirus also contains human coronavirus HCoV-OC43, SARS-HCoV, HCoV-HKU1, MERS-CoV, SARS-CoV-2 (Gabutti *et al.*, 2020), whereas gammacoronavirus includes viruses infecting the whales and birds and deltacoronavirus is viruses isolated from pigs and birds (Carstens, n.d.) (Burrell *et al.*, 2017) .Mild respiratory infections are caused by human coronaviruses 229E, NL63, OC43 but there is a tendency for the virus to transform while in the infected animal into a new human coronavirus which is highly pathogenic. Three recent examples of this are SARS2 CoV2019, SARS-CoV, and MERS-CoV (*Coronavirus | Human Coronavirus Types | CDC*, n.d.).



Figure 6: Classification of coronaviruses. Based on the serology and phylogeny the coronaviruses are classified in four genera.

2.6 Pathogenesis

Infection with coronaviruses leads to degenerative changes on cilia of respiratory epithelial cells, causing ciliary stasis or loss of ciliary action. The target cells of SARS-CoV-2 are bronchial epithelial cells and type 1 and type 2 alveolar epithelial cells (Burrell *et al.*, 2017). Hyaline membrane is formed in the alveoli causing diffuse alveolar damage due to the desquamation of the alveolar epithelial cells of the lungs. This causes acute respiratory distress syndrome (ARDS) in patients. The immune reaction causes pro-inflammatory cytokines (IL-6, IL-12) and chemokines (IL-8, CCL-2, CXCL10) levels to increase in plasma. The viral load is usually the highest in the second week of the infection which continues to destroy lung epithelium. Interestingly, studies observed that SARS-CoV-2 infection severity increases with age in infected mice and primate, and the same is believed to be true in humans (Outline, 2017).

2.7 Coronavirus disease (COVID-19)

The COVID-19 is the third novel coronavirus to cause a large-scale epidemic in the twenty-first century after the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003 (Lee *et al,*2003) (Peiris *et al,*2003) (De Wit *et l,* 2016) and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012 (Alagaili *et al*, 2014) (Memish *et al* , 2013) (Zaki *et al* , 2012). In early December 2019, several patients presented with acute pneumonia with unspecific cause in Wuhan, China (WHO, 2020). A new human coronavirus was identified as the pathogen and ICTV recognized it as a variant of SARS-CoV hence named it SARS-CoV-2 (*International Committee on Taxonomy of Viruses*, n.d.). WHO named the pneumonia caused by this novel virus "COVID-19" or coronavirus disease 2019 (WHO, *Coronavirus disease 2019*, n.d.). SARS-CoV- 2 became the seventh coronavirus that infects humans. The phylogenetic analysis of the SARS- CoV-2 genome is closely, or 88%, related to two bat derived SARS-like coronavirus (bat-SL- CoVZC45 and bat-SL-CoVZXC21), but it was genetically different (79% similarity) from SARS- CoV and MERS-CoV (Lu *et al.*, 2020)(Khailany *et al.*, 2020).

2.7.1 Epidemiology

The first identified patients of this disease were workers of Huanan Seafood Wholesale Market in China. Studies showed that the intermediate host of SARS-CoV-2 was likely to be pangolins, and snakes. The major mode of transmission of this disease is human-to-human (Gabutti *et al.*, 2020).

The first case of COVID-19 outside China was confirmed in Thailand on January 13th 2020. By January 30th, there were 7711 confirmed cases in China, and 83 cases across 18 countries of the world. Hence, WHO declared this outbreak a Public Health Emergency of International Concern. Globally, as of 29 July 2021, there have been 195,886,929 confirmed cases of COVID-19, including 4,189,148 deaths, reported to WHO.

Figure 7: COVID-19 Map - Johns Hopkins Coronavirus Resource Center (jhu.edu) (Reprinted with permission "Dong E, Du H, Gardner L. *An interactive web-based dashboard to track COVID-19 in real time.* Lancet Inf Dis. 20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1")

2.7.2 Clinical Features

COVID-19 manifests with a wide clinical spectrum ranging from asymptomatic patients to septic shock and multiorgan dysfunction (Wang *et al* ,2020). COVID-19 is classified based on the severity of the presentation. The disease may be classified into mild, moderate, severe, and critical (Wang *et al* ,2020). The majority (81%) of COVID-19 cases are mild in severity (Wang *et al* ,2020). The most common symptoms of patients include fever (98.6%), fatigue (69.6%), dry cough, and diarrhea (Wang *et al* ,2020). Other associated symptoms are headache, sore throat, sputum production, confusion, and vomiting. Within 5 days of these initial symptoms, dyspnea is seen in severe cases. Diagnosis is clinical, and complications can be excluded with the help of radiographic studies. In critical cases, it progresses into acute respiratory distress syndrome (ARDS), shock, coagulation dysfunction, metabolic acidosis, and multiple organ failure (Wang *et*

al., 2020). Patients with COVID-19 and sepsis are deemed the most critically ill of them all. The accompanying multiorgan dysfunction results as a consequence of dysregulated host response to infection. Signs of organ dysfunction include: severe dyspnea, low oxygen saturation, reduced urine output, tachycardia, hypotension, cold extremities, skin mottling, and altered mentation. The fatality rate of this infection studied on May 2020 was 3.46% (Harapan *et al.*, 2020) (Liu *et al.*, 2020). Patients with pre-existing comorbidities have a higher case fatality rate. These comorbidities include diabetes (7.3%), respiratory disease (6.5%), cardiovascular disease (10.5%), hypertension (6%), and oncological complications (5.6%) (Wang *et al* ,2020).

2.7.3 Laboratory diagnosis

Laboratory tests include the specific detection of the virus using a nasal swab, tracheal aspirate, or bronchoalveolar lavage samples, or saliva samples - detected by reverse-transcription polymerase chain reaction (RT-PCR), or by enzyme-linked immunoassay (ELISA) (**Figure 8**). Though genome sequencing is an accurate way to detect the virus, due to its complexity and high cost, RT-PCR is the most common, useful, and direct method for detecting SAR-CoV-2 in respiratory secretions and blood. The nasopharyngeal swab is used for RT-PCR, but improper sampling and contaminated samples are major drawbacks causing false results (Wang *et al.*, 2020). ELISA is also used to detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) targeting the SARS-CoV-2 from blood samples (**Figure 8**). IgM/IgG antibody detection tests are another sensitive tool for both diagnosis and patient follow-up.



Figure 8: Comparison of SARS-CoV-2/COVID-19 test types and techniques. (Reprinted with permission American Society for Microbiology, 2020).

CHAPTER 3

COVID-19: RISKS TO HEALTHCARE WORKERS

WHO director-general, Dr. Tedros Adhanom Ghebreyesus, gave an estimate during his opening remarks at the World Health Assembly on May 27, 2021 stating, "At least 115,000 health and care workers have now died from Covid-19 around the world" (Weiss *et al*, 2011). Adding to his description, the International Council of Nurse (ICN) chief executive said "These 115,000 deaths are the equivalent of a commercial airliner crashing with no survivors every day for the past 17 months since the pandemic started. It is a disgrace." (Weiss *et al*, 2011) .

In the process of the continued commitment and efforts to save lives, many get infected and succumb to this pandemic. Each and every effort made to reduce the rate of infection to healthcare workers is an added layer of protection against the infection. Though priority is vaccination, as the different variants evolve, there are still strong guidelines that need to be followed to reduce transmission (WHO, 2004). Hence reduction of the viral load in saliva using an oral antiseptic should be helpful to healthcare professionals performing procedures in close contact to patients.

3.1 Review of oral antiseptics used during a global pandemic

Many solutions of antiseptics such as povidone-iodine (PVP-I), alcohol with essential oils, chlorhexidine (CHX), hydrogen peroxide (HP) and iota-carrageenan (IC) are widely used and safe for application to the epithelium (Stathis *et al* , 2021). Hypertonic saline has also been investigated as an intervention against respiratory infections (Hsieh et al,2020). WHO Interim guidance for dental practices recommends asking patients to rinse their mouths with 1% hydrogen peroxide, or 0.2% PVP-I, for 20 s prior to examination or starting any dental procedure to reduce the salivary load of oral microbes, including SARS-CoV-2 (Woo et al, 2010). The American Dental Association (ADA) and the Center for Disease Control and Prevention (CDC) (https://www.cdc.gov/coronavirus/2019-ncov/hcp/dental-settings.html) have also recommended the use of preprocedural mouthwashes before oral procedures.

3.2 Common Oral antiseptics

3.2.1 Povidone Iodine (PVP-I)

PVP-I is an iodophor solution containing a water-soluble complex of iodine and polyvinylpyrrolidone (PVP) with broad microbicidal activity. Free iodine, slowly liberated from the polyvinylpyrrolidone iodine (PVPI) complex in solution, kills eukaryotic or prokaryotic cells through iodination of lipids and oxidation of cytoplasmic and membrane compounds (Stathis *et al* , 2021). This agent exhibits a broad range of microbicidal activity against bacteria, fungi, protozoa, and viruses. Slow release of iodine from the PVPI complex in solution minimizes iodine toxicity towards mammalian cells. (Anderson *et al*,2020). It is typically used in a 1% concentration for mucositis, prophylaxis of oropharyngeal infections, and prevention of ventilator-associated pneumonia (Pelletier *et al*,2020). Its antimicrobial action occurs after free iodine dissociates from polyvinylpyrrolidone, then iodine rapidly penetrates microbes to disrupt proteins and oxidizes nucleic acid structures - causing microbial death. Its effectiveness has been well demonstrated through many *in vitro* studies against multiple viruses, including SARS-CoV, MERS-CoV, and influenza virus A (H1N1) (Xu *et al*,2020) (Ashish Jain *et al*,2020).

3.2.2 Chlorhexidine (CHX)

CHX is a broad-spectrum antiseptic that acts against Gram-positive and Gram-negative bacteria, aerobes, facultative anaerobes, and fungus by increasing the permeability of the bacterial cell wall, causing its lysis. CHX is used in dentistry to reduce dental plaque and treat periodontal disease (Stathis *et al*, 2021). Evidence indicates an *in vitro* effect against lipid-enveloped viruses such as influenza A, parainfluenza, herpes virus 1, cytomegalovirus, and hepatitis B (Meister *et al*,2020). Although COVID-19 is an enveloped virus, 0.12% CHX gluconate was suggested to have little or no effect against coronaviruses when compared with other mouthwashes (Koch-Heier *et al*,2020). However, some researchers suggested that after 2 hours, its use would be beneficial for the control of COVID-19 transmission (Pelletier *et al,* 2021).

3.2.3 Hydrogen Peroxide (H2O2)

H2O2 has been used in dentistry alone or combined with salts since the start of the century. As a mouthwash, it is an odourless, clear, and colourless liquid. Lack of an adverse soft tissue effect was found in many studies of 1%–1.5% H_2O_2 used as a daily rinse over two years follow-up (Stathis *et al*, 2021). An *in vitro* study found that 3% H_2O_2 effectively inactivated adenovirus types 3 and 6, adeno-associated virus type 4, rhinoviruses 1A, 1B, and type 7, myxoviruses, influenza A and B, respiratory syncytial virus, strain long, and coronavirus strain 229E within 1–30 minutes, discovering that coronaviruses and influenza viruses were the most sensitive. Since SARS-CoV-2 is vulnerable to oxidation, preprocedural oral rinses containing oxidative agents such as 1% H_2O_2 have been suggested to reduce the salivary viral load (Gottsauner *et al*, 2020).

3.2.4 Essential Oils

LISTERINE Antiseptic is an antimicrobial mouthwash composed of 3 essential oils (eucalyptol, menthol, and thymol) that has been clinically proven to kill germs that cause plaque and gingivitis. Although recent *in vitro* studies have reported that LISTERINE Mouthwash has activity against enveloped viruses, including coronavirus, the available data is insufficient. No evidence- based clinical conclusions can be drawn with regards to the anti-viral efficacy of this product at this time (Meister *et al ,* 2020) (Davies *et al,* 2020).

3.2.5 Cetylpridinium Chloride (CPC)

CPC is a quaternary ammonium compound that is safe for use in humans (Green *et al*, 2021). CPC 0.05% has been used to reduce dental plaque and gingivitis as an alternative in patients who develop mucosal irritation and stains related to CHX. The antiviral effect of CPC has been demonstrated in influenza patients, significantly reducing the duration and severity of cough and sore throat (Green *et al*, 2021) (Jordana *et al*, 2021). Hypotheses about a possible action on SARS-CoV-2 are based on its lysosomotropic mechanism of action and its ability to destroy viral capsids. These findings indicate that CPC could be effective against other enveloped viruses such as coronaviruses (Stathis *et al*, 2021).

While gargles cannot replace the use of traditional personal protective equipment (i.e., gowns, masks, protective eyewear and gloves), the use of oral antiseptics has the potential to be useful for

combating SARS-CoV-2. Clinical trials are definitely warranted to assess the benefits of these compounds, and their possible roles in mitigating disease progress and transmission of SARS-CoV-2 .

The aim of this thesis is to better understand, and to evaluate, antiseptic oral rinse efficacy in minimizing the transmission of SARS-CoV-2 from patients to healthcare workers while performing AGMP. The next chapter will describe methods to do this.

CHAPTER 4

MATERIAL AND METHODS

4.1 Focused question

The literature search strategy and methods for this systematic review were specified in a protocol conducted according to PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews) statement (Tricco *et al*, 2018). The tested hypothesis was to establish if antiseptic oral rinses could minimize transmission of COVID-19 infection to healthcare professionals. Ethical approval or informed consent was not required for this study, as the analyses were carried out based on previously published data.

4.2 Literature search strategy and data sources

A combination of Cochrane, PubMed, and Embase databases from inception up to June 2021 was used for this systematic review. The keywords included but were not restricted to: 'mouthwash', 'mouth rinse', 'rinse', 'oral rinse', 'gargle' AND 'coronavirus', 'COVID', 'SARS-CoV-2. After the electronic search of all the published and unpublished database, a hand search of the selected papers was done to study of the most recent research data to understand in depth the role of oral rinse in minimizing the transmission of COVID-19.

4.3 Study selection: inclusion and exclusion criteria

The inclusion criteria were as follows: 1) *In vitro*, *in vivo*, and randomized clinical trials that studied the use of mouthwashes or oral rinses to reduce the viral load of SARS-CoV-2; 2) having no language restriction; and 3) unlimited study period. The exclusion criteria were as follows:1) case reports, 2) systematic reviews; and 3) animal studies.

4.4 Data extraction

Two independent reviewers performed data extraction using customized data retrieval forms. Extracted data included authors, year of publication, study design (*in vivo* or *in vitro*), type of SARS-CoV-2 strain, biochemical technique employed for detecting the virus, tested products,

concentrations or type of intervention, duration, key findings, details of funding (funding source), and conflict of interest.



Figure 9: Flowchart of strategy for literature search and selection.

CHAPTER 5

RESULTS

5.1 Study selection

In order to perform a high-level overview of primary research data on a focused question utilizing high quality evidence, a systematic review was performed following the flowchart shown in **Figure 9**. A total of 665 potentially relevant records were identified through an electronic database search and a gray literature search. After removing duplicates, 639 records were screened by the reviewers for title and abstract content, of which additional 437 records were excluded. Full texts of 55 articles were reviewed for eligibility assessment, and 24 records were included in the review based on the inclusion/exclusion criteria. The reasons for excluding 31 articles are presented in **Figure 9,** and listed in the protocol in **Appendix 1: Supplementary Material – Study Protocol**.

5.2 Study characteristics

The study characteristics of the included articles are presented in **Table 1**. Of the 24 articles in this review, 17 were *in vitro* studies and 7 were *in vivo* studies. All *in vitro* studies used a standardized methodology (endpoint dilution assay) to evaluate the efficacy of antiseptic formulations against SARS-CoV-2. Briefly, endpoint dilution assay determines the amount of virus required to kill 50% of infected hosts, or to produce a cytopathogenic effect in 50% of inoculated tissue culture cells. Data for viral activity are usually reported as log10 reduction value (LRV), which denotes reduction in viral titers, with experimental test group compared to virus control group. A log10 reduction rate of ≥4 represents 99.999% kill efficacy (Pelletier *et al*, 2020. The *in vivo* studies were done utilizing RT-PCR assay of samples obtained from saliva or nasopharyngeal secretion swab or oropharyngeal gargle samples, or a combination of both nasopharyngeal and oropharyngeal swabs.

Table 1: Study characteristics of the 17 *in vitro* included articles in this chapter.

Author	Year	Study Design	Country	Type of SARS-CoV-2 strain	Method	Main ingredient tested	Duration
Meister *et al*	2020 Sept	*In vitro*	*Germany*	UKEssen strain (strain 1), BetaCoV/Germany/Ulm/01/2020 (strain 2), BetaCoV/Germany/Ulm/02/2020 (strain 3)	CCID50	1.5%H2O2, 0.2% CHX,1,0% PVP-I, OCT, PAPB, DQ+BZK, Eucalyptol 0.091%+ Thymol 0.063%+Menthol 0.042%	30 s
Bidra *et al*	2020 June	*In vitro*	*USA*	USA-WA1/2020	CCID50	0.5%, 1.25%, 1.5% PVP-I and 1.5, 3% H2O2	15 s and 30 s
Bidra *et al*	2020 July	*In vitro*	*USA*	USA-WA1/2020	CCID50	PVP-I (0.5%, 1.25%, 1.5%)	15 s and 30 s
Anderson *et al*	2020 July	*In vitro*	*Singapore*	hCoV-19/Singapore/2/2020	TCID50/mL	10%, 7.5%, 1%, 0.45% PVP-I	30 s
Pelletier *et al*	2020 Sept	*In vitro*	*USA*	USA-WA1/2020	CCID50	1% to 5% PVP-I	60 s
Xu *et al*	2020 Dec	*In vitro*	*USA*	USA-WA1/2020	Fluorescent Intensity	10% PVP-I, 1.5% H2O2, 0.12% CHX and 20-30% Ethanol	20 s
Hassandarvish *et al*	2020 Dec	*In vitro*	*Malaysia*	MY/UM/6-3; TIDREC	TCID50/mL	1% PVP-I	30 s and 60 s
Ashish Jain *et al*	2020 Dec	*In vitro*	*India*	strain not specified	qRT-PCR	0.2% and 0.12% CHX 2% PVP-1	30 s and 60 s
Meyers *et al*	2020 Sept	*In vitro*	*USA*	HCoV-229e	TCID50/mL	1.5%H2O2, 1.5%H2O2 +0.1 Menthol, 0.7%CPC, 5%PVP-I, Eucalyptol(0.092%)+ Menthol+Thymol(0.064%)	30 s, 1 min, and 2 min
Statkute *et al*	2020 Nov	*In vitro*	*UK*	England 2	PFU/100µl	7% ethanol+0.2%CHX, 0.05-0.1%CPC, 21%ethanol, 0.07-0.1% CPC + 0.05 sodium citric acid, 7.5%PVP-I	30 s
Muñoz-Basagoiti *et al*	2020 Dec	*In vitro*	*Spain*	pNL4-3.Luc.R-E and SARS-CoV-2.SctΔ19	TCID50/mL	(1.47mM CPC+1.33mM CHX) , 2.063mM CPC	2 min
Katrin Steinhauer *et al*	2020 Oct	*In vitro*	*Germany*	Isolated SARS-CoV-2 outbreak strain	TCID50/mL	Different commercially availabile concentrations of CHX, OCT	15 s, 1 min and < 5min
Katherine Davies *et al*	2020 Dec	*In vitro*	*UK*	England 2	TCID50/mL	0.2% CHX with alcohol, 0.2%CHX without alcohol, 1.4% dipotassium oxalate, 0.01-0.02% hypochlorous acid, 1.5%H2O2, 0.58% PVP-I, Eucalyptol+thymol+menthol	1 min
Green *et al*	2020 Oct	*In vitro*	*UK*	HCoV-229e	TCID50/mL	0.07% CPC, 15.7% ethanol, 0.2% zinc sulphate heptahydrate and mix of amyloglucosidase, glucose oxidase, lysozyme,lactoferrin.	30 s and 60s
Luca Cegolon *et al*	2020 Nov	*In vitro*	*Italy*	Recombinant vesicular stomatitis virus (rVSV) combined with the Spike (S) protein of SARS-CoV-2 (rVSV-S)	IC50	OSCN and LF	0, 20, 40, and 60 min
Eriko Ohgitani *et al*	2020 Dec	*In vitro*	*Japan*	Japan/AI/I-004/2020	TCID50/mL	Black, green and oolong tea	10 s and 1 min
Koch-Heier *et al*	2021 Mar	*In vitro*	*Germany*	SARS-CoV-2; Isolate "FI-100"	PFU/ml	0.05% CPC and 1.5% H2O2, 0.1% CHX, 0.05% CPC, and 0.005% F	30 s

* H2O2- Hydrogen peroxide, PVP-I -Povidone Iodine, CHX- Chlorhexidine, CPC- Cetylpyridinium Chloride, OSCN- Hypothiocyanite, LF- Lactoferrin, DQ- Dequalinium Chloride, BZK- Benzalkonium chloride, OCT- Octenident, PAPB- Polyaminopropyl Biguanide, min- minutes, s – seconds.

Table 2: Study characteristics of the seven *in vivo* included articles in this chapter.

Author	Year	Study Design	Country	Number of patients	Method	Testing products or intervention	Duration
Lamas *et al.*	2020 July	*In vivo*	Spain	4	RT-PCR	1% H2O2 and 0.2% PVP-I	1 min
Gottsauner *et al.*	2020 Oct	*In vivo*	Germany	10	RT-PCR	1% H2O2	30 s
Seneviratne *et al.*	2020 Dec	*In vivo*	Singapore	16	RT-PCR	PVP-I, CHX and CPC	30 s
Capetti *et al.*	2020 Sept	*In vivo*	Italy	6	RT-PCR	3% H2O2	30 s
Avhad *et al.*	2020 Oct	*In vivo*	India	40	RT-PCR	0.2% CHX	2X/day - 1 week
Huang *et al.*	2021 March	*In vivo*	USA	684	RT-PCR	0.12% CHX	30 s
Guenezan *et al.*	2021 Feb	*In vivo*	France	24	RT-PCR	1% PVP-I	15 s

* H2O2- Hydrogen peroxide, PVP-I -Povidone Iodine, CHX- Chlorhexidine, CPC- Cetylpyridinium Chloride, min- minutes, s – seconds, RT-PCR – Real-time polymerase chain reaction.

5.2.1 Povidone iodine (PVP-I)

The search strategy yielded a total of thirteen studies reporting on the efficacy of PVP-I against SARS-CoV-2 (Meister *et al*,2020),(Bidra *et al*,2020),(Bidra *et al*,2020), (Anderson et al,2020), (Pelletier et al ,2020), (Xu et al, 2020), (Hassandarvish et al,2020), (Ashish Jain et al,2020)(Meyers *et al*, 2020),(Statkute *et al*,2020), (Lamas *et al*,2020),(Seneviratne *et al*,2020), (Guenezan *et al*, 2021). Except for 3 *in vivo* studies (Lamas *et al*,2020) (Seneviratne *et al*,2020) (Guenezan *et al*,2021), the remaining studies had an *in vitro* study design. The concentration of PVP-I used in *in vitro* studies ranging from 0.20 to 1.50 % and a contact time varying from 15 seconds to 2 minutes. The collective results of these *in vitro* studies demonstrated that PVP-I caused a significant reduction in viral titers of SARS-CoV-2 with log10 reduction values (LRVs) greater than or equal to 4 log 10 reduction of SARS-CoV-2 titers. This corresponds to over 99.999% kill of the virus by all the percentages of PVP-I. These studies showed that the virus was completed inactivated at the lowest concentration (0.5%) with a short time exposition of 15 seconds.

5.2.2 Chlorhexidine (CHX)

A total of ten studies were found that reported the efficacy of chlorhexidine against SARS- CoV-2 (Xu *et al*,2020) (Ashish Jain *et al*,2020) (Statkute *et al*,2020) (Katrin Steinhauer *et al*,2020) (Katherine Davies *et al*,2020) (Seneviratne *et al*,2020) (Avhad *et al*,2020) (Huang *et al*,2020) (Meister *et al*,2020) (Koch-Heier *et al*,2020). Except for 3 *in vitro* studies (Seneviratne *et al*,2020) (Avhad *et al*,2020) (Huang *et al*,2020), the remainder had an *in vivo* study design. Meister *et al.* using the *in vitro* end point dilution assay method, evaluated viral efficacy of 2 commercial preparations of chlorhexidine (Chlorhexamed Forte and Dynexidine Forte 0.2%) against 3 different strains of SARS-CoV-2 [UKEssen strain (strain 1); BetaCoV/Germany/Ulm/01/2020 (strain2); BetaCoV/Germany/Ulm/02/2020 (strain 3)] and demonstrated minimal benefit (LRV = 0.50–1.17). Regarding *in vivo* efficacy, Huang *et al.* evaluated the effectiveness of a 0.12% chlorhexidine gluconate mouth rinse for 30 seconds on salivary viral load in 684 patients with confirmed COVID-19. The RT-PCR analysis demonstrated the presence of SARS-CoV-2 in baseline saliva samples of all patients, and a transient (2 hours) decrease in SARS-CoV-2 salivary load after CHX mouth rinse.

5.2.3 Hydrogen peroxide (H_2O_2)

The literature search yielded eight studies evaluating the anti–SARS-CoV-2 efficacy of hydrogen peroxide (H_2O_2), with 5 *in vitro* and *3 in vivo* study designs (Xu *et al*,2020) (Bidra *et al*,2020) (Koch-Heier *et al*,2020) (Meyers *et al*,2020) (Katherine Davies *et al*,2020) (Lamas *et al*,2020) (Capetti *et al*,2020) (Gottsauner *et al*,2020) (Meister *et al*,2020). Bidra *et al.* demonstrated limited viral activity of 3% and 5% H_2O_2 when tested for either 15 or 30 seconds duration, with LRVs ranging from 1.00 to 1.33. This LRV for H_2O_2 was three times lower than the LRV obtained with any of the concentrations of PVP-I tested in their study (Bidra *et al*,2020). These findings were confirmed by Meister *et al.* demonstrating an LRV of <1 with commercial H_2O_2–based oral rinse (Cavex pre mouth rinse). However, another study concluded that 0.2 and 0.12% inactivated more than 99.9% of SARS-CoV-2 virus, in minimal contact time of 30 seconds (Capetti *et al*,2020). On the other hand, seven other publications, including *in vivo studies,* showed only a minimal effect of hydrogen peroxide against SARS-CoV-2.

5.2.4 Essential oils

Only four *in vitro* studies reported on anti–SARS-CoV-2 efficacy of essential oil–based mouth rinse (Listerine Cool Mint) (Meyers *et al*,2020) (Statkute *et al*,2020) (Green *et al*,2020) (Meister *et al*,2020). The study using a fifty-percent tissue culture infective dose (TCID 50), a measure of infectious virus titer, reported a viral titer reduction of three orders of magnitude with Listerine in comparison to the control group (Meyers *et al*,2020) (Green *et al*,2020).

5.2.5 Cetylpridinium choride (CPC)

Six studies reported on the efficacy of CPC against SARS-CoV-2 (Koch-Heier et al,2020) (Meyers et al,2020) (Green et al,2020) (Statkute et al,2020) (Muñoz-Basagoiti et al,2020) (Seneviratne et al,2020). One study was in vivo (Seneviratne et al,2020), while the other 5 had an in vitro study design. The in vitro study used a concentration of 0.05-0.1% CPC with a contact time varying from 30 seconds to 2 minutes. The collective results of these studies demonstrate that CPC caused a significant reduction in viral titers of SARS-CoV-2 with LRV values greater than or equal to 4 log 10 reduction of SARS-CoV-2 titers (Koch-Heier et al,2020) (Meyers et al,2020) (Green et al,2020). Statkute et al. conducted an in vitro study of England 2 type of SARS-CoV2 for 30 seconds to compare the antiviral activity between CPC containing mouth rinse and PVP- I

containing one. The results showed complete elimination of the virus by CPC and 99.9% inactivation with PVP-I.

CHAPTER 6

DISCUSSION

Frontline healthcare professionals play a vital role in the prevention, management, and treatment of COVID-19 outbreaks in the world. In face of a constant virus exposure, the death rate among these professionals, before vaccines were distributed, was significant. The CDC and ADA recommended preprocedural prophylactic antiseptic oral rinse to potentially reduce the SARS-CoV-2 viral load in patients, to protect the healthcare workers. However, there are several types of products, concentrations, administration-modes, and different types of tests to evaluate the risk of virus transmission. This thesis has gathered all the relevant information on using prophylactic antiseptic oral rinse, and its role in minimizing the transmission of SARS-CoV-2, and performed a systematic review, and a comprehensive analysis, to help stakeholders minimize virus transmission to healthcare professionals exposed to oral secretions.

The studies included in the final review, mostly focused on evaluating **PVP-I mouth rinses** (Meister *et al*,2020) (Bidra *et al*,2020) (Anderson *et al*,2020) (Pelletier *et al*,2020) (Xu *et al*,2020) (Hassandarvish *et al*,2020) (Ashish Jain *et al*,2020) (Meyers *et al*,2020) (Statkute *et al*,2020) (Lamas *et al*,2020) (Seneviratne *et al*,2020) (Guenezan *et al*,2021) CHX (Xu *et al*,2020) (Ashish Jain *et al*,2020) (Statkute *et al*,2020) (Katrin Steinhauer *et al*,2020) (Katherine Davies *et al*,2020) (Seneviratne *et al*,2020) (Avhad *et al*,2020) (Huang *et al*,2020) (Meister *et al*,2020) (Koch-Heier *et al*,2020), H2O2 (Xu *et al*,2020) (Bidra *et al*,2020) (Koch-Heier *et al*,2020) (Meyers *et al*,2020) (Katherine Davies *et al*,2020) (Lamas *et al*,2020) (Capetti *et al*,2020) (Gottsauner *et al*,2020) (Meister *et al*,2020), essential oil–based (Meyers *et al*,2020) (Statkute *et al*,2020) (Green *et al*,2020) (Meister *et al*,2020), and CPC (Koch-Heier *et al*,2020) (Meyers *et al*,2020) (Green *et al*,2020) (Statkute *et al*,2020) (Muñoz-Basagoiti *et al*,2020) (Seneviratne *et al*,2020). PVP-I is a mouth rinse widely used as presurgical antiseptic in clinical practice due to the broad-spectrum antimicrobial activity. This product acts by releasing free iodine, which disrupts microbial metabolic pathways and destabilizes structural components of cell membranes of pathogens (Fine PD, 1985). There are some concerns about staining of teeth and tissues due to the iodine content in PVP-I; however, a clinical trial study showed that PVP-I causes less pigmentation in the teeth compared to CPC and CHX. The concentration of PVP-I tested in most of the studies included in

this review (Meister *et al*,2020) (Bidra *et al*,2020) (Anderson *et al*,2020) (Pelletier *et al*,2020) (Xu *et al*,2020) (Hassandarvish *et al*,2020) (Ashish Jain *et al*,2020) (Meyers *et al*,2020) is below the recommended safe concentration of 5% for oral use (Frank *et al,* 2020). Ready-to-use PVP-I mouth rinse is not available in some countries; however, it is possible to dilute this product to an appropriate concentration prior to oral use (Frank *et al,* 2020). In relation to *in vitro* studies involving PVP-I efficacy, PVP-I has demonstrated very promising results to significantly reduce (99.99%) the virucidal activity against SARS-CoV-2. However, these experiments were done in laboratory settings, which may significantly differ from a clinical scenario. Currently, the data from *in vivo* research are limited to only a few studies (Lamas *et al*,2020) (Seneviratne *et al*,2020) (Guenezan *et al*,2021), with small sample size populations. In order to draw better conclusions and make clinical recommendations, it is necessary to conduct a well-designed clinical trial with an adequate number of patients in each intervention, and to use proper control groups and methods.

CHX, a broad-spectrum biocide, was the second most investigated mouthwash to reduce COVID-19 virus under *in vitro* laboratory conditions, and *in vivo* tests using different concentrations of 0.1%, 0.12% and 0.2% for 30 seconds (Xu *et al*,2020) (Ashish Jain *et al*,2020) (Statkute *et al*,2020) (Katrin Steinhauer *et al*,2020) (Katherine Davies *et al*,2020) (Seneviratne *et al*,2020) (Avhad *et al*,2020) (Huang *et al*,2020) (Meister *et al*,2020) (Koch-Heier *et al*,2020). Using *in vitro* experiments, Meister *et al.* and Xu *et al.*, showed that CHX was 0.01% more effective than PVP-I. In similar manner, an *in vivo* study conducted by Huang *et al.* testing 0.12% CHX for 30 seconds in 684 patients showed a significant reduction in the viral load and these authors recommended CHX as an effective preprocedural oral rise to prevent the spread of this virus.

Use of **H_2O_2**, a widely used antiseptic in healthcare, has been advocated during COVID-19 pandemic as an oral rinse. The available evidence from *in vitro* and *in vivo* studies (Xu *et al*,2020) (Bidra *et al*,2020) (Koch-Heier *et al*,2020) (Meyers *et al*,2020) (Katherine Davies *et al*,2020) (Lamas *et al*,2020) (Capetti *et al*,2020) (Gottsauner *et al*,2020) (Meister *et al*,2020) considering concentrations of 1%, 1.5%, and 3% for a minimum contact period of 15 seconds (Bidra *et al*,2020) did not yield encouraging outcomes. Most of the studies showed minimal virucidal activity *in vitro* of H_2O_2 as oral rinse. Furthermore, Gotttsauner *et al.* performed an *in vivo* study with 10 patients and concluded that 1% H_2O_2 had no effect against SARS-CoV-2 viral load.

There are few studies showing results on the efficacy of **essential oil–based mouth rinse (Listerine**) to provide some protection in preventing viral transmission (Meyers *et al*,2020) (Statkute *et al*,2020) (Green *et al*,2020) (Meister *et al*,2020). Meyers *et al.* and Green *et al.* concluded that a combination of essential oils might be helpful but did not significantly decrease viral action. Similarly, CPC has reported promising preliminary results as an anti-COVID mouthwash with reduction in the viral titer (Koch-Heier *et al*,2020) (Meyers *et al*,2020) (Green *et al*,2020) (Statkute *et al*,2020) (Muñoz-Basagoiti *et al*,2020) (Seneviratne *et al*,2020); however, results are based on only a few studies so further clinical validation is necessary. There is also concern about considerable teeth stains after using CPC mouthwash. It is important to note that for the *in vitro* studies, a large variety of SARS-CoV-2 strain types were used.

While COVID-19 research is being published at an astonishingly fast pace, and the published material has limitations, it is imperative that current and potential recommendation options be frequently re-evaluated to offer the best possible protection under current unprecedented circumstances. Future research on the efficacy of antiseptics oral rinses should focus on reporting factors such as exposure time, strength, volume of mouth rinse, and SARS-CoV-2 strain, so that results can be extrapolated to the clinical setting. Similarly, clinical studies should have adequate sample size and control groups to yield more reliable conclusions and have better external validity. Furthermore, factors such as baseline viral titer load, patient demographics, and symptomatology should also be considered and reported to match patient data and to provide a better understanding of results.

CHAPTER 7

CONCLUSION AND FUTURE DIRECTIONS

Healthcare professionals performing AGMP are at increased risk for infection and death by COVID-19. Use of a preprocedural prophylactic antiseptic oral rinse can minimize the risk of SARS-CoV-2 transmission in healthcare workers. There has been great variability in practice, along with a plethora of recommendations that differed amongst institutions as to pre-procedure oral solutions. Experimental and clinical research studies have shown that using pre-procedure antiseptic solutions, such as products containing polyvinylpyrrolidone iodine (PVP-I), chlorhexidine gluconate (CHG), cetylpyridinium chloride (CPC), chlorine dioxide (ClO2), essential oils, and hydrogen peroxide (H2O2) can reduce viral load.

Considering different products and concentrations, results from previous studies summarized in the current thesis have suggested that PVP-I and CPC are the most clinical effective preprocedural oral rinse methods to reduce SARS-CoV-2 viral load in saliva, thereby potentially best-protecting healthcare professionals. It is hoped that this information will help protect health professionals exposed to high viral load during AGMP.

Future research is needed to better determine the most effective pre-procedure rinse solution that reduces SARS-CoV-2 viral load in saliva, the optimal concentration, exposure time, volume of mouth rinse and potential side effects, so that results can be extrapolated to the clinical setting. A blinded randomized controlled parallel group design trial with adequate sample size is likely to yield more reliable conclusions.

Finally considering the highly contagious new Delta variant, it would be useful to determine if daily use of antiseptic oral rinses in infected patients for 2-4 weeks post-infection might prevent virus shedding and potential transmission to others.

BIBLIOGRAPHY

REFERENCES

Azzi, L., Carcano, G., Gianfagna, F., Grossi, P., Dalla, D., Genoni, A., Fasano, M., Sessa, F., Tagliabue, A., & Baj, A. (2020). Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ' s public news and information . January.

Peiris, J. S. M. (2012). Coronaviruses. *Medical Microbiology: Eighteenth Edition*, 587–593. https://doi.org/10.1016/B978-0-7020-4089-4.00072-X

Harapan, H., Itoh, N., Yufika, A., Winardi, W., Keam, S., Te, H., Megawati, D., Hayati, Z., Wagner, A. L., & Mudatsir, M. (2020). Coronavirus disease 2019 (COVID-19): A literature review. *Journal of Infection and Public Health*, *13*(5), 667–673. https://doi.org/10.1016/j.jiph.2020.03.019

https://www.who.int/health-topics/coronavirus

To, K. K. W., Tsang, O. T. Y., Leung, W. S., Tam, A. R., Wu, T. C., Lung, D. C., Yip, C. C. Y., Cai, J. P., Chan, J. M. C., Chik, T. S. H., Lau, D. P. L., Choi, C. Y. C., Chen, L. L., Chan, W. M., Chan, K. H., Ip, J. D., Ng, A. C. K., Poon, R. W. S., Luo, C. T., … Yuen, K. Y. (2020). Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases*, *20*(5), 565–574. https://doi.org/10.1016/S1473-3099(20)30196-1

To, K. K. W., Tsang, O. T. Y., Yip, C. C. Y., Chan, K. H., Wu, T. C., Chan, J. M. C., Leung, W. S., Chik, T. S. H., Choi, C. Y. C., Kandamby, D. H., Lung, D. C., Tam, A. R., Poon, R. W. S., Fung, A. Y. F., Hung, I. F. N., Cheng, V. C. C., Chan, J. F. W., & Yuen, K. Y. (2020). Consistent Detection of 2019 Novel Coronavirus in Saliva. *Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America*, *71*(15), 841–843. https://doi.org/10.1093/cid/ciaa149

Young, B. E., Ong, S. W. X., Kalimuddin, S., Low, J. G., Tan, S. Y., Loh, J., Ng, O. T., Marimuthu, K., Ang, L. W., Mak, T. M., Lau, S. K., Anderson, D. E., Chan, K. S., Tan, T. Y., Ng, T. Y., Cui, L., Said, Z., Kurupatham, L., Chen, M. I. C., … Lye, D. C. (2020). Epidemiologic Features and Clinical Course of Patients Infected with SARS-CoV-2 in Singapore. *JAMA - Journal of the American Medical Association*, *323*(15), 1488–1494. https://doi.org/10.1001/jama.2020.3204

Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., Diaz, G., Cohn, A., Fox, L. A., Patel, A., Gerber, S. I., Kim, L., Tong, S., Lu, X., Lindstrom, S., … Pillai, S. K. (2020). First case of 2019 novel coronavirus in the United States. *New England Journal of Medicine*, *382*(10), 929–936. https://doi.org/10.1056/NEJMoa2001191

Xiao, F., Tang, M., Zheng, X., Liu, Y., Li, X., & Shan, H. (2020). Evidence for Gastrointestinal Infection of SARS-CoV-2. *Gastroenterology*, *158*(6), 1831-1833.e3. https://doi.org/10.1053/j.gastro.2020.02.055

Bescos, R., Casas-Agustench, P., Belfield, L., Brookes, Z., & Gabaldón, T. (2020). Coronavirus Disease 2019 (COVID-19): Emerging and Future Challenges for Dental and Oral Medicine. *Journal of Dental Research*, *99*(9), 1113. https://doi.org/10.1177/0022034520932149

Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, *et al.* PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. *Ann Intern Med*. (2018) 7:467–73. doi: 10.7326/M18-0850

Wang, L.-F.; Shi, Z.; Zhang, S.; Field, H.; Daszak, P.; Eaton, B.T. Review of bats and SARS. Emerg. Infect. Dis. 2006, 12, 1834–1840.

Ge, X.-Y.; Li, J.; Yang, X.; Chmura, A.; Zhu, G.; Epstein, J.H.; Mazet, J.K.; Hu, B.; Zhang, W.; Peng, C.; et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013, 503, 535–538

Cui, J.; Li, F.; Daszak, P. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Genet. 2018, 17, 181–192.

Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al. COVID-19 diagnosis and management: a comprehensive review. J Internal Med 288(2):192–206. doi: 10.1111/joim.13091

Chen, Y.; Liu, Q.; Guo, D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J. Med. Virol. 2020, 92, 418–423.

Zhuang Z, Zhao S, Lin Q, Cao P, Lou Y, Yang L, et al. Preliminary estimates of the reproduction number of the coronavirus disease(COVID-19) outbreak in Republic of Korea and Italy by 5 March 2020. Int J Infect Dis (2020) 95:308–10. doi: 10.1016/j.ijid.2020.04.044

Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020, 181, 271–280.e8. [Google Scholar] [CrossRef]

Li, W.; Moore, M.J.; Vasilieva, N.; Sui, J.; Wong, S.K.; Berne, M.A.; Somasundaran, M.; Sullivan, J.L.; Luzuriaga, K.; Greenough, T.C.; et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003, 426, 450–454. [Google Scholar] [CrossRef]

Alanagreh L, Alzoughool F, Atoum M. The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. Pathogens. 2020 Apr 29;9(5):331. doi: 10.3390/pathogens9050331. PMID: 32365466; PMCID: PMC7280997.

https://www.scribd.com/document/480291620/Curs-Covid19-pdf

Qian, Z.; Travanty, E.A.; Oko, L.; Edeen, K.; Berglund, A.; Wang, J.; Ito, Y.; Holmes, K.V.; Mason, R.J. Innate immune response of human alveolar Type II cells infected with severe acute respiratory syndrome–coronavirus. Am. J. Respir. Cell Mol. Boil. 2013, 48, 742–748. [Google Scholar] [CrossRef] [PubMed]

Letko, M.; Marzi, A.; Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 2020, 5, 562–569. [Google Scholar] [CrossRef] [PubMed]

Masters, P.S. The Molecular Biology of Coronaviruses; Elsevier: Amsterdam, The Netherlands, 2006; Volume 66, pp. 193–292.

Lee, N.; Hui, D.S.; Wu, A.; Chan, P.K.S.; Cameron, P.; Joynt, G.; Ahuja, A.T.; Yung, M.Y.; Leung, C.; To, K.; et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. New Engl. J. Med. 2003, 348, 1986–1994. [Google Scholar] [CrossRef]

Peiris, J.; Lai, S.; Poon, L.L.; Guan, Y.; Yam, L.; Lim, W.; Nicholls, J.M.; Yee, W.; Yan, W.; Cheung, M.; et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361, 1319–1325. [Google Scholar] [CrossRef]

De Wit, E.; Van Doremalen, N.; Falzarano, D.; Munster, V. SARS and MERS: Recent insights into emerging coronaviruses. Nat. Rev. Genet. 2016, 14, 523–534. [Google Scholar] [CrossRef]

Lee, N.; Hui, D.S.; Wu, A.; Chan, P.K.S.; Cameron, P.; Joynt, G.; Ahuja, A.T.; Yung, M.Y.; Leung, C.; To, K.; et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. New Engl. J. Med. 2003, 348, 1986–1994. [Google Scholar] [CrossRef]

Peiris, J.; Lai, S.; Poon, L.L.; Guan, Y.; Yam, L.; Lim, W.; Nicholls, J.M.; Yee, W.; Yan, W.; Cheung, M.; et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361, 1319–1325. [Google Scholar] [CrossRef]

De Wit, E.; Van Doremalen, N.; Falzarano, D.; Munster, V. SARS and MERS: Recent insights into emerging coronaviruses. Nat. Rev. Genet. 2016, 14, 523–534. [Google Scholar] [CrossRef]

Alagaili, A.N.; Briese, T.; Mishra, N.; Kapoor, V.; Sameroff, S.C.; De Wit, E.; Munster, V.; Hensley, L.E.; Zalmout, I.S.; Kapoor, A.; et al. Middle east respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio 2014, 5, e00884-14. [Google Scholar] [CrossRef] [PubMed]

Memish, Z.A.; Mishra, N.; Olival, K.J.; Fagbo, S.; Kapoor, V.; Epstein, J.H.; AlHakeem, R.; Durosinloun, A.; Al Asmari, M.; Islam, A.; et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg. Infect. Dis. 2013, 19, 1819–1823. [Google Scholar] [CrossRef] [PubMed]

Zaki, A.M.; Van Boheemen, S.; Bestebroer, T.; Osterhaus, A.D.; Fouchier, R.A.M. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. New Engl. J. Med. 2012, 367, 1814–182.

Organization WH. Rolling updates on coronavirus disease (COVID-19) (2020). Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen (Accessed 11 March 2020).

https://covid19.who.int/

Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Co Lefkowitz ronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse. J Prosthodont. 2020 Jul;29(6):529-533. doi: 10.1111/jopr.13209. Epub 2020 Jun 16. PMID: 32511851; PMCID: PMC7300649.

Anderson DE, Sivalingam V, Kang AEZ, Ananthanarayanan A, Arumugam H, Jenkins TM, Hadjiat Y, Eggers M. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease. Infect Dis Ther. 2020 Sep;9(3):669-675. doi: 10.1007/s40121-020-00316-3. Epub 2020 Jul 8. PMID: 32643111; PMCID: PMC7341475.
Pelletier, J. S., Tessema, B., Frank, S., Westover, J. B., Brown, S. M., & Capriotti, J. A. (2021). Efficacy of Povidone-Iodine Nasal and Oral Antiseptic Preparations Against Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2). Ear, Nose & Throat Journal, 100(2_suppl), 192S-196S. https://doi.org/10.1177/0145561320957237

Xu C, Wang A, Hoskin ER, Cugini C, Markowitz K, Chang TL, Fine DH. Differential effects of antiseptic mouth rinses on SARS-CoV-2 infectivity in vitro. bioRxiv [Preprint]. 2020 Dec 1:2020.12.01.405662. doi: 10.1101/2020.12.01.405662. Update in: Pathogens. 2021 Mar 01;10(3): PMID: 33299988; PMCID: PMC7724656.

Hassandarvish P, Tiong V, Mohamed NA, Arumugam H, Ananthanarayanan A, Qasuri M, Hadjiat Y, Abubakar S. In vitro virucidal activity of povidone iodine gargle and mouthwash against SARS-CoV-2: implications for dental practice. Br Dent J. 2020 Dec 10:1–4. doi: 10.1038/s41415-020-2402-0. Epub ahead of print. PMID: 33303923; PMCID: PMC7726738.

Jain A, Grover V, Singh C, Sharma A, Das DK, Singh P, Thakur KG, Ringe RP. Chlorhexidine: An effective anticovid mouth rinse. J Indian Soc Periodontol. 2021 Jan-Feb;25(1):86-88. doi: 10.4103/jisp.jisp_824_20. Epub 2021 Jan 7. PMID: 33642749; PMCID: PMC7904017.

Meyers C, Robison R, Milici J, Alam S, Quillen D, Goldenberg D, Kass R. Lowering the transmission and spread of human coronavirus. J Med Virol. 2021 Mar;93(3):1605-1612. doi: 10.1002/jmv.26514. Epub 2020 Oct 5. PMID: 32940907. https://www.biorxiv.org/content/10.1101/2020.11.13.381079v2

Jordana Muñoz-Basagoiti, Daniel Perez-Zsolt, Rubén León, Vanessa Blanc, Dàlia Raïch-Regué, Mary CanoSarabia, Benjamin Trinité, Edwards Pradenas, Julià Blanco, Joan Gispert, Bon aventura Clotet, Nuria Izquierdo-Useros Cetylpyridinium chloride-containing mouthwashes reduce the infectivity of SARS-CoV-2 variants in vitro
bioRxiv 202012.21.423779; doi: https://doi.org/10.1101/2020.12.21.423779

Evelina Statkute, Anzelika Rubina, Valerie B O'Donnell, David W. Thomas, Richard J. Stanton Brief Report: The Virucidal Efficacy of Oral Rinse Components Against SARS-CoV-2 In Vitro bioRxiv 2020.11.13.381079; doi: https://doi.org/10.1101/2020.11.13.381079

K. Steinhauer, T.L. Meister, D. Todt, A. Krawczyk, L. Paßvogel, B. Becker, D. Paulmann, B. Bischoff, S. Pfaender, F.H.H. Brill, E. Steinmann, Comparison of the in-vitro efficacy of different mouthwash solutions targeting SARS-CoV-2 based on the European Standard EN 14476,Journal of Hospital Infection,Volume 111,2021,Pages 180-183,ISSN 0195-6701,https://doi.org/10.1016/j.jhin.2021.01.031.

Davies K, Buczkowski H, Welch SR, Green N, Mawer D, Woodford N, Roberts ADG, Nixon PJ, Seymour DW, Killip MJ. Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes. J Gen Virol. 2021 Apr;102(4). doi: 10.1099/jgv.0.001578. PMID: 33913803.

Green, G. Roberts, T. Tobery, C. Vincent, M. Barili, C. Jones In vitro assessment of the virucidal activity of four mouthwashes containing Cetylpyridinium Chloride, ethanol, zinc and a mix of enzyme and proteins against a human coronavirus bioRxiv 2020.10.28.359257; doi: https://doi.org/10.1101/2020.10.28.359257

Cegolon L, Mirandola M, Salaris C, Salvati MV, Mastrangelo G, Salata C. Hypothiocyanite and Hypothiocyanite/Lactoferrin Mixture Exhibit Virucidal Activity In Vitro against SARS-CoV-2. Pathogens. 2021 Feb 19;10(2):233. doi: 10.3390/pathogens10020233. PMID: 33669635; PMCID: PMC7922920.

Ohgitani, E.; Shin-Ya, M.; Ichitani, M.; Kobayashi, M.; Takihara, T.; Kawamoto, M.; Kinugasa, H.; Mazda, O. Rapid Inactivation In Vitro of SARS-CoV-2 in Saliva by Black Tea and Green Tea. *Pathogens* 2021, *10*, 721. https://doi.org/10.3390/pathogens10060721

Koch-Heier J, Hoffmann H, Schindler M, Lussi A, Planz O. Inactivation of SARS-CoV-2 through Treatment with the Mouth Rinsing Solutions ViruProX® and BacterX® Pro. Microorganisms. 2021 Mar 3;9(3):521. doi: 10.3390/microorganisms9030521. PMID: 33802603; PMCID: PMC8002120.

Martínez Lamas, L, Diz Dios, P, Pérez Rodríguez, MT, *et al.* Is povidone iodine mouthwash effective against SARS-CoV-2? First in vivo tests. Oral Dis. 2020; 00: 1– 4. https://doi.org/10.1111/odi.13526

Gottsauner MJ, Michaelides I, Schmidt B, Scholz KJ, Buchalla W, Widbiller M, Hitzenbichler F, Ettl T, Reichert TE, Bohr C, Vielsmeier V, Cieplik F. A prospective clinical pilot study on the effects of a hydrogen peroxide mouthrinse on the intraoral viral load of SARS-CoV-2. Clin Oral Investig. 2020 Oct;24(10):3707-3713. doi: 10.1007/s00784-020-03549-1. Epub 2020 Sep 2. PMID: 32876748; PMCID: PMC7464055.

Seneviratne CJ, Balan P, Ko KKK, Udawatte NS, Lai D, Ng DHL, Venkatachalam I, Lim KS, Ling ML, Oon L, Goh BT, Sim XYJ. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection. 2021 Apr;49(2):305-311. doi: 10.1007/s15010-020-01563-9. Epub 2020 Dec 14. PMID: 33315181; PMCID: PMC7734110.

Capetti AF, Borgonovo F, Morena V, Lupo A, Cossu MV, Passerini M, Dedivitiis G, Rizzardini G. Short-term inhibition of SARS-CoV-2 by hydrogen peroxide in persistent nasopharyngeal

carriers. J Med Virol. 2021 Mar;93(3):1766-1769. doi: 10.1002/jmv.26485. Epub 2020 Sep 24. PMID: 32881014; PMCID: PMC7891345.

Avhad, S. K.; Bhanushali, M.; Sachdev, S. S.; Save, S. S.; Kalra, D.; Kamala, D. N..Comparison of effectiveness of chlorine dioxide mouthwash and chlorhexidine gluconate mouthwash in reduction of oral viral load in patients with covid-19 *Indian Journal of Public Health Research and Development ; 11(11):27-32, 2020.*Article | EMBASE | ID: covidwho-995314

Huang, YH, Huang, JT. Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients. J Med Virol. 2021; 93: 4370- 4373. https://doi.org/10.1002/jmv.26954

Guenezan J, Garcia M, Strasters D, Jousselin C, Lévêque N, Frasca D, Mimoz O. Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2021 Apr 1;147(4):400-401. doi: 10.1001/jamaoto.2020.5490. PMID: 33538761; PMCID: PMC7863011.

Meister TL, Brüggemann Y, Todt D, Conzelmann C, Müller JA, Groß R, Münch J, Krawczyk A, Steinmann J, Steinmann J, Pfaender S, Steinmann E. Virucidal Efficacy of Different Oral Rinses Against Severe Acute Respiratory Syndrome Coronavirus 2. J Infect Dis. 2020 Sep 14;222(8):1289-1292. doi: 10.1093/infdis/jiaa471. Erratum in: J Infect Dis. 2021 Feb 13;223(3):541. PMID: 32726430; PMCID: PMC7454736.

Bidra AS, Pelletier JS, Westover JB, Frank S, Brown SM, Tessema B. Comparison of In Vitro Inactivation of SARS CoV-2 with Hydrogen Peroxide and Povidone-Iodine Oral Antiseptic Rinses. J Prosthodont. 2020 Aug;29(7):599-603. doi: 10.1111/jopr.13220. Epub 2020 Jul 24. PMID: 32608097; PMCID: PMC7361576.

O'Donnell VB, Thomas D, Stanton R, Maillard JY, Murphy RC, Jones SA, *et al.* Potential role of oral rinses targeting the viral lipid envelope in SARS-CoV-2 infection. Function. (2020) 1:zqaa002. doi: 10.1093/function/zqaa002

Fine PD. A clinical trial to compare the effect of two antiseptic mouthwashes on gingival inflammation. J Hosp Infect. (1985) 6(Suppl. A):189–93. doi: 10.1016/S0195-6701(85)80067-0

Frank S, Capriotti J, Brown SM, and Tessema B. Povidone-iodine use in sinonasal and oral cavities: a review of safety in the COVID-19 era. Ear Nose Throat J. (2020) 9:586–93. doi: 10.1177/0145561320932318

Burrell, C. J., Howard, C. R., & Murphy, F. A. (2017). Chapter 13 - Coronaviruses. Fenner and White's Medical Virology, 437–446. https://doi.org/10.1016/B978-0-12-375156-0.00031-X

Carstens, E. B. (n.d.). Introduction to Virus Taxonomy. In Virus Taxonomy. Elsevier Inc. https://doi.org/10.1016/B978-0-12-384684-6.00114-2

Cauchemez, S., Fraser, C., Van Kerkhove, M. D., Donnelly, C. A., Riley, S., Rambaut, A., Enouf, V., van der Werf, S., & Ferguson, N. M. (2014). Middle East respiratory syndrome coronavirus: Quantification of the extent of the epidemic, surveillance biases, and transmissibility. The Lancet Infectious Diseases, 14(1), 50–56. https://doi.org/10.1016/S1473-3099(13)70304-9

Coronavirus | Human Coronavirus Types | CDC. (n.d.). Retrieved May 19, 2020, from https://www.cdc.gov/coronavirus/types.html

Coronavirus disease 2019. (n.d.). Retrieved May 19, 2020, from https://www.who.int/emergencies/diseases/novel-coronavirus-2019

de Groot, R., Baker, S., Baric, R., Enjuanes, L., Gorbalenya, A., Holmes, K., Perlman, S., Poon, L., Rottier, P., Talbot, P., Woo, P., & Ziebuhr, J. (2012). Part II – The Positive Sense Single Stranded RNA Viruses Family Coronaviridae. Virus Taxonomy: Ninth Report of the International Committee on Taxonomy of Viruses, Figure 1, 806–828. https://doi.org/10.1016/B978-0-12-384684-6.00068-9

Gabutti, G., d'Anchera, E., Sandri, F., Savio, M., & Stefanati, A. (2020). Coronavirus: Update Related to the Current Outbreak of COVID-19. Infectious Diseases and Therapy. https://doi.org/10.1007/s40121-020-00295-5

Gaunt, E. R., Hardie, A., Claas, E. C. J., Simmonds, P., & Templeton, K. E. (2010). Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. Journal of Clinical Microbiology, 48(8), 2940–2947. https://doi.org/10.1128/JCM.00636-10

Gralinski, L. E., & Baric, R. S. (2015). Molecular pathology of emerging coronavirus infections. Journal of Pathology, 235(2), 185–195. https://doi.org/10.1002/path.4454

Harapan, H., Itoh, N., Yufika, A., Winardi, W., Keam, S., Te, H., Megawati, D., Hayati, Z., Wagner, A. L., & Mudatsir, M. (2020). Coronavirus disease 2019 (COVID-19): A literature review. Journal of Infection and Public Health, 13(5), 667–673. https://doi.org/10.1016/j.jiph.2020.03.019

Hulswit, R. J. G., de Haan, C. A. M., & Bosch, B. J. (2016). Coronavirus Spike Protein and Tropism Changes. In Advances in Virus Research (1st ed., Vol. 96). Elsevier Inc. https://doi.org/10.1016/bs.aivir.2016.08.004

International Committee on Taxonomy of Viruses (ICTV). (n.d.). Retrieved May 19, 2020, from https://talk.ictvonline.org/

Ison, M. G., & Lee, N. (2017). Noninfluenza Respiratory Viruses. In Infectious Diseases (Fourth Edi). Elsevier Ltd. https://doi.org/10.1016/b978-0-7020-6285-8.00173-8

Khailany, R. A., Safdar, M., & Ozaslan, M. (2020). Genomic characterization of a novel SARS-CoV-2. Gene Reports, 19(March), 100682. https://doi.org/10.1016/j.genrep.2020.100682

ison, E. J., Dempsey, D. M., Hendrickson, R. C., Orton, R. J., Siddell, S. G., & Smith, D. B. (2018). Virus taxonomy: The database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Research, 46(D1), D708–D717. https://doi.org/10.1093/nar/gkx932

Liu, Y., Gayle, A. A., Wilder-Smith, A., & Rocklöv, J. (2020). The reproductive number of COVID-19 is higher compared to SARS coronavirus. Journal of Travel Medicine, 27(2), 1–4. https://doi.org/10.1093/jtm/taaa021

Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., … Tan, W. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet, 395(10224), 565–574. https://doi.org/10.1016/S0140-6736(20)30251-8

MacKenzie, J. S., & Smith, D. W. (2020). COVID-19: A novel zoonotic disease caused by a coronavirus from China: What we know and what we don't. Microbiology Australia, 41(1), 45–50. https://doi.org/10.1071/MA20013

Masters, P. S. (2006). The Molecular Biology of Coronaviruses. Advances in Virus Research, 65(06), 193–292. https://doi.org/10.1016/S0065-3527(06)66005-3

Nakagawa, K., Lokugamage, K. G., & Makino, S. (2016). Viral and Cellular mRNA Translation in Coronavirus-Infected Cells. In Advances in Virus Research (1st ed., Vol. 96). Elsevier Inc. https://doi.org/10.1016/bs.aivir.2016.08.001

Neuman, B. W., & Buchmeier, M. J. (2016). Supramolecular Architecture of the Coronavirus Particle. In Advances in Virus Research (1st ed., Vol. 96). Elsevier Inc. https://doi.org/10.1016/bs.aivir.2016.08.005

Neuman, Benjamin W., Chamberlain, P., Bowden, F., & Joseph, J. (2014). Atlas of coronavirus replicase structure. Virus Research, 194, 49–66. https://doi.org/10.1016/j.virusres.2013.12.004

Outline, C. (2017). Coronaviridae CORONAVIRUSES of Birds. Fenner's Veterinary Viriology, 435–461. https://doi.org/10.1016/B978-0-12-800946-8.00024-6

Park, M., Thwaites, R. S., & Openshaw, P. J. M. (2020). COVID-19: Lessons from SARS and MERS. European Journal of Immunology, 50(3), 308–311. https://doi.org/10.1002/eji.202070035

Peiris, J. S. M. (2012). Coronaviruses. Medical Microbiology: Eighteenth Edition, 587–593. https://doi.org/10.1016/B978-0-7020-4089-4.00072-X

Schoeman, D., & Fielding, B. C. (2019). Coronavirus envelope protein: Current knowledge. Virology Journal, 16(1), 1–22. https://doi.org/10.1186/s12985-019-1182-0

Snijder, E. J., Decroly, E., & Ziebuhr, J. (2016). The Nonstructural Proteins Directing Coronavirus RNA Synthesis and Processing. In Advances in Virus Research (1st ed., Vol. 96). Elsevier Inc. https://doi.org/10.1016/bs.aivir.2016.08.008

Tortorici, M. A., & Veesler, D. (2019). Structural insights into coronavirus entry. In Advances in Virus Research (1st ed., Vol. 105). Elsevier Inc. https://doi.org/10.1016/bs.aivir.2019.08.002

Tyrrell, D. A., & Bynoe, M. L. (1966). Cultivation of viruses from a high proportion of patients with colds. Lancet, 1(7428), 76–77. https://doi.org/10.1016/S0140-6736(66)92364-6

Velavan, T. P., & Meyer, C. G. (2020). The COVID-19 epidemic. Tropical Medicine and International Health, 25(3), 278–280. https://doi.org/10.1111/tmi.13383

Wang, Y., Wang, Y., Chen, Y., & Qin, Q. (2020). Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures. Journal of Medical Virology, 92(6), 568–576. https://doi.org/10.1002/jmv.25748

Weiss, S. R., & Leibowitz, J. L. (2011). Coronavirus pathogenesis. In Advances in Virus Research (1st ed., Vol. 81). Elsevier Inc. https://doi.org/10.1016/B978-0-12-385885-6.00009-2

WHO. (2004). WHO guidelines for the global surveillance of severe acute respiratory syndrome (SARS) Updated recommendations, October 2004. October, 40. http://www.who.int/csr/resources/publications/WHO_CDS_CSR_ARO_2004_1.pdf

Woo, P. C. Y., Huang, Y., Lau, S. K. P., & Yuen, K. Y. (2010). Coronavirus genomics and bioinformatics analysis. Viruses, 2(8), 1805–1820. https://doi.org/10.3390/v2081803

https://www.nursingtimes.net/news/coronavirus/who-says-at-least-115000-health-workers-have-now-died-from-covid-19-27-05-2021/

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/work.html World Health Organization. Considerations for the provision of essential oral health services in the context of COVID-19: interim guidance (2020). https://apps.who.int/iris/handle/10665/333625

https://pubchem.ncbi.nlm.nih.gov/compound/Povidone-iodine#section=European-Community-(EC)-Number

American Dental Association . 2020. ADA interim guidance for minimizing risk of COVID-19 transmission. Available from URL: https://www.kavo.com/en-us/resource-center/ada-interim-guidance-minimizing-risk-covid-19-transmission

Centers for Disease Control and Prevention. Interim infection prevention and control guidance for dental settings during the COVID-19 response. Available from URL: https://www.cdc.gov/coronavirus/2019-ncov/hcp/dental-settings.html

Stathis, C., Victoria, N., Loomis, K., Nguyen, S. A., Eggers, M., Septimus, E., & Safdar, N. (2021). Review of the use of nasal and oral antiseptics during a global pandemic. Future microbiology, 16(2), 119–130. https://doi.org/10.2217/fmb-2020-0286

"Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Inf Dis. 20(5):533-534. doi: 10.1016/S1473-3099(20)30120-1"

Hsieh, C. W., Chen, C., Su, H. C., & Chen, K. H. (2020). Exploring the efficacy of using hypertonic saline for nebulizing treatment in children with bronchiolitis: a meta-analysis of randomized controlled trials. BMC pediatrics, 20(1), 434. https://doi.org/10.1186/s12887-020- 02314-3

APPENDIX 1: SUPPLEMENTARY MATERIAL - STUDY PROTOCOL

Embase

Embase <1974 to 2021 May 21>		
#	Searches	Results
1	sars-related coronavirus/	467
2	(coronavirinae/ or betacoronavirus/ or coronavirus infection/) and (epidemic/ or pandemic/)	11332
3	(nCoV* or 2019nCoV or 19nCoV or COVID19* or COVID or SARS-COV-2 or SARSCOV-2 or SARS-COV2 or SARSCOV2 or Severe Acute Respiratory Syndrome Coronavirus 2 or Severe Acute Respiratory Syndrome Corona Virus 2).ti,ab,kw,hw,ot.	89720
4	((new or novel or "19" or "2019" or Wuhan or Hubei or China or Chinese) adj3 (coronavirus* or corona virus* or betacoronavirus* or CoV or HCoV)).ti,ab,kw,hw,ot.	84719
5	((coronavirus* or corona virus* or betacoronavirus*) adj3 (pandemic* or epidemic* or outbreak* or crisis)).ti,ab,kw,ot.	5742
6	((Wuhan or Hubei) adj5 pneumonia).ti,ab,kw,ot.	345
7	or/1-6	97331
8	limit 7 to yr="2019 -Current"	96010
9	mouthwash/	4828
10	chlorhexidine/	18100
11	povidone iodine/	10636
12	hydrogen peroxide/	97655
13	(((mouth or oral*) adj3 (rins* or wash*)) or mouthwash* or mouthrinse* or gargl*).ti,ab,kw.	8703
14	((mouth or oral*) adj3 (Chlorhex* or chlorohex* or bidex or lisium or nibitane or nolvasan or nolvascin or rotersept or sterilon or tubilicid or tubulicid or umbipro)).tw,kw.	745
15	((mouth or oral*) adj3 ((povidone adj2 iodide) or (polyvidone adj2 iodine) or betadine or beta-isodona or betaisodona or pharmadine or betaisodona or braunoderm or	28

	braunol or braunovidon or bridin* or destrobac*or iodopovidone or isodine* or polyvinylpyrrolidine iodine or polyvinylpyrrolidone iodide or polyvinylpyrrolidone iodine or povadyne or prepodyne or proviodine or PVP-I or PVP-II or PVP-1 or PVP-2 or pvp-iodine or traumasept or videne or vidine)).tw,kw.	
16	((mouth or oral*) adj3 (albone or crystacide or dihydrogen dioxide or eskata or h2o2 or hioxyl or hydrogen dioxide or (hydrogen adj2 peroxide) or hydrogen superoxide or hydrogenperoxide or microcid or oxigenal or perhydrol or pyrozone)).tw,kw.	110
17	or/9-16	131726
18	8 and 17	327
19	(exp animal/ or exp juvenile animal/ or adult animal/ or animal cell/ or animal tissue/ or nonhuman/ or animal experiment/ or animal model/) not human/	6778655
20	(animal or animals or canine* or dog or dogs or feline or ferret* or hamster* or lamb or lambs or mice or monkey or monkeys or mouse or murine or pig or pigs or piglet* or porcine or primate* or rabbit* or rats or rat or rodent* or sheep* or veterinar*).ti,kw,dq,jx. not (human* or patient*).mp.	2084060
21	18 not (19 or 20)	308

PubMed

#	Query	Results
5	#1 AND #4	146
4	#2 OR #3	80,616
3	(((mouth-wash*[Title/Abstract] OR mouth-rins*[Title/Abstract] OR oral*-wash*[Title/Abstract] OR oral*-rins*[Title/Abstract] OR mouthwash*[Title/Abstract] OR mouthrinse*[Title/Abstract] OR gargl*[Title/Abstract]) OR ((mouth[Title/Abstract] OR oral*[Title/Abstract]) AND (Chlorhex*[Title/Abstract] OR chlorohex*[Title/Abstract] OR bidex[Title/Abstract] OR lisium[Title/Abstract] OR nibitane[Title/Abstract] OR nolvasan[Title/Abstract] OR nolvascin[Title/Abstract] OR rotersept[Title/Abstract] OR sterilon[Title/Abstract] OR tubilicid[Title/Abstract] OR tubulicid[Title/Abstract] OR umbipro[Title/Abstract]))) OR ((mouth[Title/Abstract] OR oral*[Title/Abstract]) AND (povidone-iodide[Title/Abstract] OR iodide-povidone[Title/Abstract] OR polyvidone-iodine[Title/Abstract] OR iodine-polyvidone[Title/Abstract] OR betadine[Title/Abstract] OR beta-isodona[Title/Abstract] OR betaisodona[Title/Abstract] OR pharmadine[Title/Abstract] OR betaisodona[Title/Abstract] OR braunoderm[Title/Abstract] OR braunol[Title/Abstract] OR braunovidon[Title/Abstract] OR bridin*[Title/Abstract] OR destrobac*or iodopovidone[Title/Abstract] OR isodine*[Title/Abstract] OR polyvinylpyrrolidine iodine[Title/Abstract] OR polyvinylpyrrolidone iodide[Title/Abstract] OR polyvinylpyrrolidone iodine[Title/Abstract] OR povadyne[Title/Abstract] OR prepodyne[Title/Abstract] OR proviodine[Title/Abstract] OR PVP-I[Title/Abstract] OR PVP-II[Title/Abstract] OR PVP-1[Title/Abstract] OR PVP-2[Title/Abstract] OR pvp-iodine[Title/Abstract] OR traumasept[Title/Abstract] OR videne[Title/Abstract] OR vidine[Title/Abstract]))) OR ((mouth[Title/Abstract] OR oral*[Title/Abstract]) AND (albone[Title/Abstract] OR crystacide[Title/Abstract] OR dihydrogen dioxide[Title/Abstract] OR eskata[Title/Abstract] OR h2o2[Title/Abstract] OR hioxyl[Title/Abstract] OR hydrogen dioxide[Title/Abstract] OR hydrogen-peroxide[Title/Abstract] OR hydrogen superoxide[Title/Abstract] OR hydrogenperoxide[Title/Abstract] OR microcid[Title/Abstract] OR oxigenal[Title/Abstract] OR perhydrol[Title/Abstract] OR pyrozone[Title/Abstract]))	10,105

2	((("Mouthwashes"[Mesh]) OR "Chlorhexidine"[Mesh]) OR "Povidone-Iodine"[Mesh]) OR "Hydrogen Peroxide"[Mesh]	75,781
1	((Coronavirus[mh:noexp] OR Betacoronavirus[mh:noexp] OR Coronavirus Infections[mh:noexp]) AND (Disease Outbreaks[mh:noexp] OR Epidemics[mh:noexp] OR Pandemics[mh])) OR COVID-19 diagnostic testing [Supplementary Concept] OR COVID-19 drug treatment [Supplementary Concept] OR COVID-19 serotherapy [Supplementary Concept] OR COVID-19 vaccine [Supplementary Concept] OR spike glycoprotein, COVID-19 virus [Supplementary Concept] OR COVID-19 [Supplementary Concept] OR severe acute respiratory syndrome coronavirus 2 [Supplementary Concept] OR nCoV[tiab] OR nCoV[tt] OR 2019nCoV[tiab] OR 2019nCoV[tt] OR 19nCoV[tiab] OR 19nCoV[tt] OR COVID19*[tiab] OR COVID19*[tt] OR COVID[tiab] OR COVID[tt] OR SARS-CoV-2[tiab] OR SARS-CoV-2[tt] OR SARSCOV-2[tiab] OR SARSCOV-2[tt] OR SARSCOV2[tiab] OR SARSCOV2[tt] OR Severe Acute Respiratory Syndrome Coronavirus 2[tiab] OR Severe Acute Respiratory Syndrome Coronavirus 2[tt] OR ((severe acute respiratory syndrome[tiab] OR severe acute respiratory syndrome[tt]) AND (corona virus 2[tiab] OR corona virus 2[tt])) OR new coronavirus[tiab] OR (new[tt] AND coronavirus[tt]) OR novel coronavirus[tiab] OR novel coronavirus[tt] OR novel corona virus[tiab] OR (novel[tt] AND corona virus[tt]) OR novel CoV[tiab] OR (novel[tt] AND CoV[tt]) OR novel HCoV[tiab] OR (novel[tt] AND HCoV[tt]) OR (("19″[tiab] OR "19"[tt] OR "2019"[tiab] OR "2019"[tt] OR Wuhan[tiab] OR Wuhan[tt] OR Hubei[tiab] OR Hubei[tt]) AND (coronavirus*[tiab] OR coronavirus*[tt] OR corona virus*[tiab] OR corona virus*[tt] OR CoV[tiab] OR CoV[tt] OR HCoV[tiab] OR HCoV[tt])) OR ((coronavirus*[tiab] OR coronavirus*[tt] OR corona virus*[tiab] OR corona virus*[tt] OR betacoronavirus*[tiab] OR betacoronavirus*[tt]) AND (outbreak*[tiab] OR outbreak*[tt] OR epidemic*[tiab] OR epidemic*[tt] OR pandemic*[tiab] OR pandemic*[tt] OR crisis[tiab] OR crisis[tt])) OR ((Wuhan[tiab] OR Wuhan[tt] OR Hubei[tiab] OR Hubei[tt]) AND (pneumonia[tiab] OR pneumonia[tt])) AND 2019/10/31:3000/12/31[Date – Publication]	95,620

Cochrane

ID	Search	Hits
#1	(nCoV* or 2019nCoV or 19nCoV or COVID19* or COVID or SARS-COV-2 or SARSCOV-2 or SARS-COV2 or SARSCOV2 or Severe Acute Respiratory Syndrome Coronavirus 2 or Severe Acute Respiratory Syndrome Corona Virus 2):ti,ab,kw	3834
#2	((new or novel or "19" or "2019" or Wuhan or Hubei or China or Chinese) near/3 (coronavirus* or corona virus* or betacoronavirus* or CoV or HCoV)):ti,ab,kw	1717
#3	((coronavirus* or corona virus* or betacoronavirus*) near/3 (pandemic* or epidemic* or outbreak* or crisis)):ti,ab,kw	273
#4	((Wuhan or Hubei) near/5 pneumonia):ti,ab,kw	20
#5	#1 or #2 or #3 or #4	4254
#6	(((mouth or oral*) near/3 (rins* or wash*)) or mouthwash* or mouthrinse* or gargl*):ti,ab,kw	4735
#7	((mouth or oral*) near/3 (Chlorhex* or chlorohex* or bidex or lisium or nibitane or nolvasan or nolvascin or rotersept or sterilon or tubilicid or tubulicid or umbipro)):ti,ab,kw	450
#8	((mouth or oral*) near/3 ((povidone near/2 iodide) or (polyvidone near/2 iodine) or betadine or beta-isodona or betaisodona or pharmadine or betaisodona or braunoderm or braunol or braunovidon or bridin* or destrobac*or iodopovidone or isodine* or polyvinylpyrrolidine iodine or polyvinylpyrrolidone iodide or polyvinylpyrrolidone iodine or povadyne or prepodyne or proviodine or PVP-I or PVP-II or PVP-1 or PVP-2 or pvp-iodine or traumasept or videne or vidine)):ti,ab,kw	89
#9	((mouth or oral*) near/3 (albone or crystacide or dihydrogen dioxide or eskata or h2o2 or hioxyl or hydrogen dioxide or (hydrogen near/2 peroxide) or hydrogen superoxide or hydrogenperoxide or microcid or oxigenal or perhydrol or pyrozone)):ti,ab,kw	107
#10	#6 or #7 or #8 or #9	5011
#11	#5 AND #10	43